Baseline characteristics of the study population
| Characteristic | PBI-4050 alone | PBI-4050+nintedanib | PBI-4050+pirfenidone |
| Subjects n | 9 | 16 | 16 |
| Age years | |||
| Mean | 71.6 | 69.4 | 66.1 |
| Median | 69.0 | 72.0 | 65.5 |
| Range | 65.0–84.0 | 46.0–83.0 | 58.0–80.0 |
| Sex n (%) | |||
| Male | 6 (66.7) | 12 (75.0) | 13 (81.3) |
| Female | 3 (33.3) | 4 (25.0) | 3 (18.8) |
| Race n (%) | |||
| White | 9 (100.0) | 15 (93.8) | 16 (100.0) |
| Other | 0 | 1 (6.3) | 0 |
| Height cm | |||
| Mean | 168.0 | 170.8 | 171.5 |
| Median | 172.0 | 171.0 | 170.5 |
| Range | 151.0–178.0 | 157.0–186.0 | 153.0–193.0 |
| Weight kg | |||
| Mean | 76.8 | 76.3 | 89.0 |
| Median | 78.8 | 74.5 | 86.2 |
| Range | 61.5–87.0 | 57.5–97.0 | 62.1–130.4 |
| BMI kg·m−2 | |||
| Mean | 27.3 | 26.1 | 30.4 |
| Median | 26.6 | 25.7 | 28.4 |
| Range | 23.4–35.1 | 23.3–31.0 | 23.8–55.7 |
| Duration of IPF disease years | |||
| Mean | 2.80 | 1.84 | 1.24 |
| Median | 2.1 | 1.7 | 0.9 |
| Range | 0.8–5.4 | 0.0–5.9 | 0.1–5.7 |
| Stage of IPF disease n (%)# | |||
| Mild | 5 (55.6) | 9 (56.3) | 6 (37.5) |
| Moderate | 4 (44.4) | 6 (37.5) | 8 (50.0) |
| Severe | 0 | 1 (6.3) | 2 (12.5) |
| HRCT compatible with UIP pattern n (%)¶ | |||
| Definite | 9 (100.0) | 15 (93.8) | 14 (93.3) |
| Possible | 0 | 1 (6.3) | 1 (6.7) |
| FVC % pred¶ | |||
| Mean | 83.1 | 71.3 | 70.8 |
| Median | 79.0 | 69.0 | 68.0 |
| Range | 58.0–109.0 | 45.0–107.0 | 45.0–100.0 |
| FVC mL¶ | |||
| Mean | 2884 | 2761 | 2849 |
| Median | 2650 | 2735 | 2930 |
| Range | 1750–4380 | 1290–3480 | 1580–4280 |
| DLCO % pred¶ | |||
| Mean | 45.2 | 50.8 | 49.1 |
| Median | 47.0 | 53.0 | 45.0 |
| Range | 27.0–64.0 | 24.0–70.0 | 23.0–83.0 |
BMI: body mass index; IPF: idiopathic pulmonary fibrosis; HRCT: high-resolution computed tomography; UIP: usual interstitial pnuemonia; FVC: forced vital capacity; DLCO: diffusing capacity of the lung for carbon monoxide. #: stage as determined by the investigator; ¶: data based on efficacy population.